(Cardiac allograft vasculopathy nowadays)

Cardiac allograft vasculopathy: recent developments.

Cardiac allograft vasculopathy (CAV) continues to limit the long-term success of cardiac transplantation. Recent insights have underscored the fact that innate and adaptive immune responses are involved in the pathogenesis of CAV. Vascular lesions are the result of cumulative endothelial injuries induced both by alloimmune responses and by nonspecific insults (including ischemia-reperfusion inj...

Cardiac allograft vasculopathy: a review.

Cardiac allograft vasculopathy (CAV) is a major factor limiting long-term survival after cardiac transplantation. CAV is an accelerated form of coronary artery disease (CAD) that is characterized by concentric fibrous intimal hyperplasia along the length of coronary vessels. Both immunologic and nonimmunologic risk factors contribute to the development of CAV by causing endothelial dysfunction ...

Coronary stenting in cardiac allograft vasculopathy.

OBJECTIVE The purpose of this study was to evaluate acute angiographic success, in-hospital complications and long-term outcome after intracoronary stenting in patients with cardiac allograft vasculopathy. BACKGROUND The application of conventional interventional modalities to treat discrete lesions in patients with cardiac allograft vasculopathy is associated with higher procedural morbidity...

Angioplasty versus stenting for cardiac allograft vasculopathy

Cardiac Allograft Vasculopathy: Past, Present and Future!

Cardiac Allograft Vasculopathy (CAV) is a serious complication after heart transplantation in adults as well as children and once developed irreversibly compromises the outcome of the recipients. Human leukocyte antigen mismatches, number and duration of rejection episodes, type of immunosuppression and presence of antibody -mediated rejection are among the most relevant immunological risk fact...